Zentalis Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Zentalis Pharmaceuticals Inc.
- Former names
- Zeno Pharma, LLC
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ZNTL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001725160
- EIN
- 82-3607803
Board of directors
-
Cam Gallagher · Director · President, Interim CFOSince 2023
-
David Michael Johnson · DirectorSince 2023
-
Diana Hausman · DirectorSince 2023
-
Enoch Kariuki · DirectorSince 2023
-
Jan Skvarka · DirectorSince 2023
-
Julia Marie Eastland · Director · CEO & PresidentSince 2024
-
Kimberly Blackwell · Director · Chief Executive OfficerSince 2023
-
Luke Nathaniel Walker · DirectorSince 2024
-
Scott Dunseth Myers · DirectorSince 2024
-
Shannon Campbell · DirectorSince 2026
Chief executives
Kimberly Blackwell
· Chief Executive Officer
Dates unknown
Julia Marie Eastland
· CEO & President
Since November 2024
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.4%
Board connections
9 of this board's directors also sit on 11 other boards.
- via Jan Skvarka and Kimberly Blackwell
- via David Michael Johnson
- via Shannon Campbell
- via Julia Marie Eastland
- via Scott Dunseth Myers
- via Kimberly Blackwell
- via Luke Nathaniel Walker
- via Diana Hausman
- via Julia Marie Eastland
- via Cam Gallagher
- via Scott Dunseth Myers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $22,924,468
- 2 purchases by 2 insiders
- Sold, last 12 months
- $10,109,656
- 10 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 14, 2026 | WALTERS GROUP 10% owner | Open-market purchase | +4,335,000 | $3.50 | $15,172,500 |
| Jun 16, 2026 | David Michael Johnson Director | Grant or award | +57,100 | — | — |
| Jun 16, 2026 | Jan Skvarka Director | Grant or award | +57,100 | — | — |
| Jun 16, 2026 | Luke Nathaniel Walker Director | Grant or award | +57,100 | — | — |
| Jun 16, 2026 | Enoch Kariuki Director | Grant or award | +57,100 | — | — |
| Jun 16, 2026 | Scott Dunseth Myers Director | Grant or award | +57,100 | — | — |
| May 26, 2026 | Shannon Campbell Director | Grant or award | +114,200 | — | — |
| Feb 10, 2026 | Vultaggio Vincent Officer (PAO and PFO) | Open-market sale | −6,894 | $2.42 | $16,683 |
| Feb 9, 2026 | Bruns Ingmar Officer (Chief Medical Officer) | Open-market sale | −335 | $2.39 | $801 |
| Feb 9, 2026 | Vultaggio Vincent Officer (PAO and PFO) | Open-market sale | −3,379 | $2.39 | $8,076 |
| Feb 9, 2026 | Julia Marie Eastland Director, Officer (CEO & President) | Open-market sale | −889 | $2.39 | $2,125 |
| Feb 6, 2026 | Bruns Ingmar Officer (Chief Medical Officer) | Open-market sale | −2,962 | $2.43 | $7,198 |
| Feb 6, 2026 | Vultaggio Vincent Officer (PAO and PFO) | Open-market sale | −29,951 | $2.43 | $72,781 |
| Feb 6, 2026 | Julia Marie Eastland Director, Officer (CEO & President) | Open-market sale | −7,866 | $2.43 | $19,114 |
| Feb 3, 2026 | Vultaggio Vincent Officer (PAO and PFO) | Open-market sale | −556 | $2.52 | $1,401 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.